CN102596189A - 抑制粘蛋白分泌的方法 - Google Patents

抑制粘蛋白分泌的方法 Download PDF

Info

Publication number
CN102596189A
CN102596189A CN2010800492171A CN201080049217A CN102596189A CN 102596189 A CN102596189 A CN 102596189A CN 2010800492171 A CN2010800492171 A CN 2010800492171A CN 201080049217 A CN201080049217 A CN 201080049217A CN 102596189 A CN102596189 A CN 102596189A
Authority
CN
China
Prior art keywords
composition
guaifenesin
administering
effective amount
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800492171A
Other languages
English (en)
Chinese (zh)
Inventor
H·阿尔布雷希特
K·C·金
J·西格雷夫
B·K·鲁宾
G·索罗芒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Reckitt Benckiser NV
Original Assignee
Reckitt Benckiser NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US12/558,517 external-priority patent/US20110065744A1/en
Priority claimed from GBGB1002039.4A external-priority patent/GB201002039D0/en
Application filed by Reckitt Benckiser NV filed Critical Reckitt Benckiser NV
Publication of CN102596189A publication Critical patent/CN102596189A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN2010800492171A 2009-09-12 2010-09-13 抑制粘蛋白分泌的方法 Pending CN102596189A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US12/558,517 2009-09-12
US12/558,517 US20110065744A1 (en) 2009-09-12 2009-09-12 Method Of Inhibiting Mucin Secretion
GB1002039.4 2010-02-09
GBGB1002039.4A GB201002039D0 (en) 2010-02-09 2010-02-09 Method of inhibiting mucin secretion
PCT/GB2010/051525 WO2011030163A1 (en) 2009-09-12 2010-09-13 Use of guaifenesin for inhibiting mucin secretion

Publications (1)

Publication Number Publication Date
CN102596189A true CN102596189A (zh) 2012-07-18

Family

ID=42941393

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2010800492171A Pending CN102596189A (zh) 2009-09-12 2010-09-13 抑制粘蛋白分泌的方法

Country Status (12)

Country Link
EP (1) EP2475360A1 (https=)
JP (1) JP2013504554A (https=)
KR (1) KR20120068889A (https=)
CN (1) CN102596189A (https=)
AU (1) AU2010294008B2 (https=)
BR (1) BR112012005517A2 (https=)
CA (1) CA2773611A1 (https=)
MX (1) MX2012003042A (https=)
MY (1) MY161187A (https=)
RU (1) RU2012114323A (https=)
WO (1) WO2011030163A1 (https=)
ZA (1) ZA201201822B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1206995A1 (en) * 2012-04-06 2016-01-22 The Uab Research Foundation Methods for increasing cftr activity
KR102211605B1 (ko) * 2018-02-26 2021-02-04 대한민국 개구리 배아를 이용한 기도 뮤신 분비 억제제의 스크리닝 방법

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA963590B (en) * 1995-05-10 1996-11-19 Adcock Ingram Ltd Pharmaceutical composition
US6846799B1 (en) * 1998-08-18 2005-01-25 The Regents Of The University Of California Preventing airway mucus production by administration of EGF-R antagonists
US7985420B2 (en) * 2000-04-28 2011-07-26 Reckitt Benckiser Inc. Sustained release of guaifenesin combination drugs
CA2474016A1 (en) * 2002-02-04 2003-08-14 Pharmacia Corporation A combination for treating cold and cough
AU2004249775A1 (en) * 2003-06-19 2004-12-29 Genaera Corporation Mucin synthesis inhibitors
US20050095288A1 (en) * 2003-11-03 2005-05-05 Andrx Labs, Llc Decongestant and expectorant tablets
US20050266032A1 (en) * 2003-12-17 2005-12-01 Sovereign Pharmaceuticals, Ltd. Dosage form containing multiple drugs
US20080014261A1 (en) * 2006-07-12 2008-01-17 Giordano John A Non-narcotic biphasic release compositions and methods for treatment of coughing, sneezing, rhinorrhea, and/or nasal obstruction
US20090202633A1 (en) * 2008-01-03 2009-08-13 Siva Ramakrishna Velaga Extended release formulations of guaifenesin

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
徐怀诚: "愈创木酚甘油醚对HIV感染病人鼻和鼻窦炎的治疗作用", 《国际耳鼻咽喉头颈外科杂志》 *

Also Published As

Publication number Publication date
AU2010294008A1 (en) 2012-04-05
KR20120068889A (ko) 2012-06-27
JP2013504554A (ja) 2013-02-07
ZA201201822B (en) 2013-05-29
EP2475360A1 (en) 2012-07-18
CA2773611A1 (en) 2011-03-17
WO2011030163A1 (en) 2011-03-17
MY161187A (en) 2017-04-14
BR112012005517A2 (pt) 2016-04-19
MX2012003042A (es) 2012-05-29
AU2010294008B2 (en) 2014-08-14
RU2012114323A (ru) 2013-10-20

Similar Documents

Publication Publication Date Title
Zanasi et al. A reappraisal of the mucoactive activity and clinical efficacy of bromhexine
TWI586663B (zh) 作為葡萄糖神經醯胺合成酶抑制劑的genz 112638 半酒石酸鹽之非結晶形與結晶形式
Lambade et al. Schwannoma of the cheek: clinical case and literature review
CN110251677A (zh) 用于治疗肺纤维化的药物组合物及其应用
Huang et al. High glucose disrupts autophagy lysosomal pathway in gingival epithelial cells via ATP6V0C
Pan et al. Huangqi shengmai Yin ameliorates myocardial fibrosis by activating Sirtuin3 and inhibiting TGF-β/Smad pathway
Gremmler et al. Proteolytic enzyme therapy in complementary oncology: a systematic review
CN102596189A (zh) 抑制粘蛋白分泌的方法
Guo et al. Ginsenoside Rg1/ADSCs supplemented with hyaluronic acid as the matrix improves rabbit temporomandibular joint osteoarthrosis
Huang et al. Signal converter‐based therapy platform promoting aging bone healing by improving permeability of the mitochondrial membrane
Yan et al. Targeted soluble epoxide hydrolase inhibits M1 macrophage polarization to improve cartilage injury in temporomandibular joint osteoarthritis
Miyata et al. Current opinion of muco-active drug research: strategies and problems
US20110065744A1 (en) Method Of Inhibiting Mucin Secretion
Kuroda et al. Perturbation of lamellar granule secretion by sodium caprate implicates epidermal tight junctions in lamellar granule function
CN117881650A (zh) β淀粉样蛋白寡聚化的抑制剂及其治疗用途
Chultemsuren et al. Ultrastructural Study of Ciliary Fragmentation in Renal Tubules During Ischemia-Reperfusion Injury
US9682072B2 (en) Compositions and methods for treatment of lung dysfunction
Yuanhu et al. Effects of substance P on growth of fibroblast-like cells derived from bile duct: anin vitrocell culture study
Wolffs et al. Calcium-sensing receptor antagonism as a novel therapeutic for pulmonary fibrosis
JP7328696B2 (ja) 角膜上皮細胞走化促進剤
Heras et al. Sphingosine-1-phosphate–sphinganine-1-phosphate Imbalance Drives Airway Hyperreactivity
Shebani Ultrastructural Studies of the Airway Epithelium in Airway Diseases
Ang et al. Primary sinonasal ameloblastoma in a Filipino female
Maeda et al. Tgif1-deficiency impairs osteoclast differentiation through PP2A-mediated ERK1/2 dephosphorylation and attenuates bone loss in mice
Tang et al. Innovative biomimetic nanoplatform for targeted therapy of ligamentum flavum hypertrophy via modulating macrophage polarization and lactic acid metabolism

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20120718